UK-based life science investor Syncona has launched a new company – Slingshot Therapeutics – with a mission to find promising projects in academia and translate them into full-blown develop
AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end